Asurvey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation

Blood

Volumn 118, Issue 18, 2011, Pages 4798-4807

  Neven, Bénédicte ^a,b   Magerus Chatinet, Aude ^a,b   Florkin, Benoit ^c   Gobert, Delphine ^a,b   Lambotte, Olivier ^d   De Somer, Lien ^e   Lanzarotti, Nina ^a   Stolzenberg, Marie Claude ^a   Bader Meunier, Brigitte ^a   Aladjidi, Nathalie ^f   Chantrain, Christophe ^g   Bertrand, Yves ^h   Jeziorski, Eric ⁱ   Leverger, Guy ^j   Michel, Gérard ^k   Suarez, Felipe ^a   Oksenhendler, Eric ^l   Hermine, Olivier ^a,b   Blanche, Stéphane ^a   Picard, Capucine ^a,b,m   Fischer, Alain ^a,b   Rieux Laucat, Frédéric ^a,b   more..

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Centre Hospitalier Universitaire   (Belgium)

^d BICÊTRE HOSPITAL   (France)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^h Hopitaux Civils de Lyon   (France)

ⁱ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^j ARMAND TROUSSEAU HOSPITAL   (France)

^k TIMONE HOSPITAL   (France)

^l SAINT LOUIS HOSPITAL   (France)

^m IMAGINE INSTITUTE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD20 ANTIBODY; FAS ANTIGEN; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; FAS PROTEIN, HUMAN;

ADULT; AGED; AUTOIMMUNE DISEASE; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; CHILD; CONTROLLED STUDY; CYTOPENIA; FEMALE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN TISSUE; HYPERSPLENISM; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PATIENT MONITORING; POSTOPERATIVE COMPLICATION; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; REVIEW; SCHOOL CHILD; SEPSIS; SOMATIC MUTATION; SPLENECTOMY; ADOLESCENT; ARTICLE; BLOOD; COHORT ANALYSIS; GENETICS; INFANT; INFORMATION PROCESSING; MIDDLE AGED; MUTATION; PHYSIOLOGY;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD95; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DATA COLLECTION; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; MUTATION; YOUNG ADULT;

EID: 80855128784     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-347641     Document Type: Review

References (37)

1. Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatr. 1967;70(6):891-899.
2. Straus SE, Jaffe ES, Puck JM, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood. 2001;98(1):194-200.
3. Sneller MC, Straus SE, Jaffe ES, et al. A novel lymphoproliferative/ autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest. 1992;90(2):334-341.
4. Rieux-Laucat F, Fischer A, Deist FL. Cell-death signaling and human disease. Curr Opin Immunol. 2003;15(3):325-331. (Pubitemid 36645110)
5. Magerus-Chatinet A, Stolzenberg MC, Loffredo MS, et al. FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. Blood. 2009;113(13):3027-3030.
6. Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81(6):935-946.
7. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268:1347-1349.
8. Drappa J, Vaishnaw AK, Sullivan KE, Chu J-L, Elkon KB. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med. 1996;335:1643-1649. (Pubitemid 26392729)
9. Holzelova E, Vonarbourg C, Stolzenberg MC, et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med. 2004;351(14):1409-1418. (Pubitemid 39288167)
10. Dowdell KC, Niemela JE, Price S, et al. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. Blood. 2010;115(25):5164-5169.
11. Chun HJ, Zheng L, Ahmad M, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature. 2002;419(6905):395-399.
12. Wang J, Zheng L, Lobito A, et al. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell. 1999;98(1):47-58. (Pubitemid 29331195)
13. Del-Rey M, Ruiz-Contreras J, Bosque A, et al. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome. Blood. 2006;108(4):1306-1312. (Pubitemid 44232029)
14. Oliveira JB, Bidere N, Niemela JE, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci U SA. 2007;104(21):8953-8958. (Pubitemid 47175418)
15. Takagi M, Shinoda K, Piao J, et al. Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. Blood. 2011;117(10):2887-2890.
16. Niemela JE, Lu L, Fleisher TA, et al. Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. Blood. 2011;117(10):2883-2886.
17. Oliveira JB, Bleesing JJ, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome: report from the 2009 NIH International Workshop. Blood. 2010;116(14):e35-e40.
18. Jackson CE, Fischer RE, Hsu AP, et al. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am J Hum Genet. 1999;64(4):1002-1014. (Pubitemid 30463031)
19. Magerus-Chatinet A, Neven B, Stolzenberg MC, et al. Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation. J Clin Invest. 2011;121(1):106-112.
20. Le Deist F, Emile JF, Rieux-Laucat F, et al. Clinical, immunological, and pathological consequences of fas-deficient conditions. Lancet. 1996;348(9029):719-723. (Pubitemid 26302308)
21. Infante AJ, Britton HA, DeNapoli T, et al. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis. J Pediatr. 1998;133(5):629-633. (Pubitemid 28521211)
22. Rieux-Laucat F, Blachere S, Danielan S, et al. Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations. Blood. 1999;94(8):2575-2582. (Pubitemid 29477285)
23. Bettinardi A, Brugnoni D, Quiros-Roldan E, et al. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood. 1997;89(3):902-909. (Pubitemid 27121283)
24. Rao VK, Price S, Perkins K, et al. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer. 2009;52(7):847-852.
25. Boulanger E, Rieux-Laucat F, Picard C, et al. Diffuse large B-cell non-Hodgkin's lymphoma in a patient with autoimmune lymphoproliferative syndrome. Br J Haematol. 2001;113(2):432-434. (Pubitemid 32523150)
26. Coignard-Biehler H, Lanternier F, de Montalembert M, et al. [Infections in splenectomized patient]. Rev Prat. 2008;58(20):2209-2214.
27. Deutsch M, Tsopanou E, Dourakis SP. The autoimmune lymphoproliferative syndrome (Canale-Smith) in adulthood. Clin Rheumatol. 2004;23(1):43-44. (Pubitemid 38247971)
28. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol. 1991;9:243-269.
29. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defect in Fas antigen that mediates apoptosis. Nature. 1992;356:314-317.
30. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the FAS ligand. Cell. 1994;76:969-976. (Pubitemid 24106378)
31. Crispín JC, Tsokos GC. Human TCR-alpha beta+ CD4- CD8- T cells can derive from CD8+ T cells and display an inflammatory effector phenotype. J Immunol. 2009;183(7):4675-4681.
32. Rao VK, Straus SE. Causes and consequences of the autoimmune lymphoproliferative syndrome. Hematology. 2006;11(1):15-23. (Pubitemid 43354955)
33. Overturf GD. American Academy of Pediatrics. Committee on Infectious Diseases. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. Pediatrics. 2000;106(2 Pt 1):367-376. (Pubitemid 30636414)
34. van den Berg A, Tamminga R, de Jong D, Maggio E, Kamps W, Poppema S. FAS gene mutation in a case of autoimmune lymphoproliferative syndrome type IA with accumulation of gammadelta+ T cells. Am J Surg Pathol. 2003;27(4):546-553. (Pubitemid 36368555)
35. Vaishnaw AK, Orlinick JR, Chu JL, Krammer PH, Chao MV, Elkon KB. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J Clin Invest. 1999;103(3):355-363. (Pubitemid 29069985)
36. Bleesing JJ, Brown MR, Straus SE, et al. Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. Blood. 2001;98(8):2466-2473.
37. Lockshin MD. Sex ratio and rheumatic disease. Autoimmun Rev. 2002;1(3):162-167. (Pubitemid 38340267)